CDKN2A and cancer: These observations suggest that the ARF and TAp73 promoters show low activity in normally growing cells and high activity in cancer cells, thereby conferring an advantage over promoters of growth-related E2F target genes, such as the E2F1 promoter, in driving cancer cell-specific gene expression [46].